최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of analytical science and technology : JAST, v.11 no.1, 2020년, pp.20 -
Chae, Yoon-Jee , Song, Yoo-Kyung , Chae, Song-Hee , Kim, Min Ju , Kang, Jong Soon , Lee, Jae-Young , Koo, Tae-Sung , Lee, Kyeong-Ryoon
AbstractLarotrectinib is an orally administered drug and the first and only selective pan-tropomyosin receptor kinase (TRK) inhibitor in clinical development to treat cancer patients harboring a neurotrophic receptor tyrosine kinase gene fusion. In this study, an analytical method to quantify the TR...
10.1136/esmoopen-2015-000023 Amatu, A, A Sartore-Bianchi and S Siena. “NTRK gene fusions as novel targets of cancer therapy across multiple tumour types.” ESMO open. 2016;1(2):e000023.
10.1038/nrn1078 Chao, MV. “Neurotrophins and their receptors: a convergence point for many signalling pathways.” Nature Reviews Neuroscience. 2003;4(4):299.
10.1016/j.canlet.2015.05.013 Creancier, L, I Vandenberghe, B Gomes, C Dejean, J-C Blanchet, J Meilleroux, R Guimbaud, J Selves and A Kruczynski. “Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.” Cancer letters. 2015;365(1):107-111.
10.1158/2159-8290.CD-15-0443 Doebele, RC, LE Davis, A Vaishnavi, AT Le, A Estrada-Bernal, S Keysar, A Jimeno, M Varella-Garcia, DL Aisner and Y Li. “An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101.” Cancer discovery. 2015:CD-15-0443.
10.1056/NEJMoa1714448 Drilon, A, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, M Nathenson, RC Doebele, AF Farago and AS Pappo. “Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.” New England Journal of Medicine. 2018;378(8):731-739.
FDA. “Bioanalytical method validation: guidance for industry.” 2018.
10.1002/bmc.4388 Lee, KR, SH Chae, MJ Kim, YJ Chae, MY Lee, CW Lee, JS Kang, WK Yoon, YS Won and K Lee. “Determination of Penicillium griseofulvum-oriented pyripyropene A, a selective inhibitor of acyl-coenzyme A: cholesterol acyltransferase 2, in mouse plasma using liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies.” Biomedical Chromatography. 2018:e4388.
10.1038/319743a0 Martin-Zanca, D, SH Hughes and M Barbacid. “A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences.” Nature. 1986;319(6056):743.
Cancer letters. A Nakagawara 169 2 107 2001 10.1016/S0304-3835(01)00530-4 Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer letters. 2001;169(2):107-14.
Drugs. LJ Scott 79 2 201 2019 10.1007/s40265-018-1044-x Scott LJ. Larotrectinib: first global approval. Drugs. 2019;79(2):201-6.
10.1016/j.jchromb.2018.10.023 Sparidans, RW, Y Wang, AH Schinkel, JH Schellens and JH Beijnen. “Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry.” Journal of Chromatography B. 2018;1102:167-172.
10.1038/ncomms5846 Stransky, N, E Cerami, S Schalm, JL Kim and C Lengauer. “The landscape of kinase fusions in cancer.” Nature communications. 2014;5:4846.
10.1016/S1535-6108(02)00180-0 Tognon, C, SR Knezevich, D Huntsman, CD Roskelley, N Melnyk, JA Mathers, L Becker, F Carneiro, N MacPherson and D Horsman. “Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma.” Cancer cell. 2002;2(5):367-376.
10.1038/ng.2938 Wu, G, AK Diaz, BS Paugh, SL Rankin, B Ju, Y Li, X Zhu, C Qu, X Chen and J Zhang. “The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.” Nature genetics. 2014;46(5):444.
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.